Pulmonx Corporation
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Pulmonx Corporation (Nasdaq: LUNG), founded in 1995 and headquartered in Redwood City, California, with additional facilities in Neuchâtel, Switzerland, develops and commercializes minimally invasive medical devices for the treatment of severe emphysema, a form of chronic obstructive pulmonary disease (COPD); its core commercially available portfolio includes the Zephyr Endobronchial Valve, an implantable one-way valve device designed to occlude airways feeding hyperinflated lung lobes to reduce hyperinflation and improve breathing; the Chartis Pulmonary Assessment System, a proprietary balloon catheter and console that measures flow and pressure to assess collateral ventilation in specific lung lobes; and the StratX Lung Analysis Platform, comprising cloud-based quantitative CT analysis services such as LungTraX Connect for workflow efficiency, LungTraX Detect for patient identification, and StratX Lung Reports detailing emphysema destruction, fissure completeness, and lobar volumes to identify optimal treatment targets. The company's products serve pulmonologists and healthcare providers treating patients with severe emphysema who remain symptomatic despite medical management, with commercial availability spanning the United States, Europe, Australia, Asia, Latin America, the Middle East, Africa, and other regions worldwide. In recent developments, Pulmonx granted 1,625,000 equity awards under its 2025 Inducement Plan on December 1, 2025, to newly hired executives including Chief Financial Officer and Chief Operating Officer Derrick Sung, as part of efforts to strengthen leadership amid Q4 2025 hires; the company also filed to register 3.2 million common shares for the same plan in November 2025, reported Q3 2025 revenue of $21.5 million reflecting 5.47% year-over-year growth, and continues to build clinical evidence supporting its technologies across patient phenotypes.
Pulmonx Rebuilds Sales Force, Targets Growth and AeriSeal Launch Next Year
What Makes Pulmonx Corporation (LUNG) a Strong Momentum Stock: Buy Now?
Pulmonx (LUNG) Upgraded to Buy: What Does It Mean for the Stock?
Pulmonx Corporation (LUNG) Q2 2026 Earnings Call Transcript
Pulmonx Q2 Earnings Call Highlights
Pulmonx Corporation (LUNG) Reports Q2 Loss, Beats Revenue Estimates
Pulmonx Reports Second Quarter 2026 Financial Results
Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference
Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026
Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026
Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulmonx Corporation (LUNG) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Pulmonx Corporation (LUNG) Q1 2026 Earnings Call Transcript
Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates
Pulmonx Reports First Quarter 2026 Financial Results
Pulmonx to Present at the Bank of America Securities 2026 Health Care Conference
Pulmonx to Report First Quarter 2026 Financial Results on April 29, 2026
Pulmonx Corporation (NASDAQ:LUNG) Given Average Rating of “Hold” by Brokerages
Pulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue Estimates